Startups

Layoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.
Backed by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for treating schizophrenia with its 2024 approval.
The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
BioSpace 40 Under 40 honoree Louisa Helms is a lot of things—athlete, scientist, entrepreneur and likely future biotech executive. Just don’t ask her to pick up any pipettes.
Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.
The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.
PRESS RELEASES